Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Search type
Keyword
Author
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Interviews
Podcasts
Videos & Webinars
News
Infographics
Society updates
Submit A Paper
Mucous Membrane Pemphigoid Shows Site-Specific Remission Patterns
November 2026
Multisite mucous membrane pemphigoid: only 45% achieved complete remission, with oral and ocular disease limiting treatment success.
Read more
2 Nov 2026
Mucous Membrane Pemphigoid Shows Site-Specific Remission Patterns
Multisite mucous membrane pemphigoid: only 45% achieved complete remission, with oral and ocular disease limiting treatment success.
30 Oct 2026
Lebrikizumab Maintains Atopic Dermatitis Response for 3 Years
Lebrikizumab maintained deep skin responses and sustained itch improvements for up to three years in early responders with moderate-to-severe atopic dermatitis, with infrequent flares among stable responders.
29 Oct 2026
Skin Toxic Effects Linked to Survival in Urothelial Cancer
Treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer overall survival.
28 Oct 2026
Melanoma Risk Models Show Moderate Predictive Performance
An Australian cohort study evaluating six melanoma risk prediction models found moderate discrimination and variable calibration, with most models underestimating observed melanoma cases.
26 Oct 2026
Auricular Acupressure Improves Rosacea Outcomes in Trial
Auricular acupressure for rosacea improved treatment success and vascular measures in a randomised, sham-controlled trial.
23 Oct 2026
Lichen Planus Linked to Increased Site-Specific Cancer Risk
Lichen planus cancer risk was elevated for oral and genital cancers in a Danish cohort, although absolute risks remained low.
21 Oct 2026
CLIPI Refines Risk Stratification in Advanced Cutaneous Lymphoma
An international study found that CLIPI scores distinguished progression risk and treatment response in advanced mycosis fungoides and Sézary syndrome, improving prognostic discrimination beyond baseline clinical stage.
15 Oct 2026
Supplement Interactions Common in Patients with Lupus
A study of 451 adults with systemic lupus erythematosus found widespread dietary supplement use and potential supplement–medication interactions in nearly one-third of participants.
Loading posts...
1
2
3
…
58
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View